Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laura Blakely"'
Autor:
Andrew Kennedy, Dianna Shipley, Max Shpak, Laura Blakely, Brian Hemphill, Kent Shih, Cassie Lane, Lisa Zimmerman, Andrew McKenzie, Mark Mainwaring, James D. Peyton, John Zubkus, David Wright, Jaswinder Singh, Johanna C. Bendell
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: This Phase II, open-label, study examined the safety of regorafenib followed by selective internal radiation therapy (SIRT) with regorafenib re-initiation in the treatment of metastatic colorectal cancer (mCRC) patients with liver metasta
Externí odkaz:
https://doaj.org/article/898c19d7c61e43eea60444c0d9590e49
Autor:
Mythili Shastry, Laura Blakely, Laura M. DeBusk, William Liggett, Brian Hemphill, John D. Hainsworth, Bertrand Anz, Robyn R. Young, Howard A. Burris, Aurelio Castrellon, Mark Mainwaring, Denise A. Yardley
Publikováno v:
Clinical breast cancer. 20(2)
Background Therapies targeting estrogen receptor signaling are standard for patients with hormone receptor (HR)-positive (HR+) metastatic breast cancer (MBC). Dysregulation of the phosphoinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian targe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76254438956ca57eb9121662f6c83049
https://pubmed.ncbi.nlm.nih.gov/31932237
https://pubmed.ncbi.nlm.nih.gov/31932237
Autor:
Michel E. Kuzur, Dianna Shipley, Mathew John Joseph, Laura Blakely, Cassie M. Lane, Mark Mainwaring, Chris Earwood, Johanna C. Bendell, Chandra Reddy, Ronald Blachly, Kirk Barnes
Publikováno v:
Cancer investigation. 35(6)
This phase-2 trial evaluated the efficacy of axitinib as maintenance therapy for patients with metastatic colorectal cancer (mCRC) following first-line treatment with FOLFOX/bevacizumab. Patients with mCRC received mFOLFOX/bevacizumab followed by axi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::692c20fb281726eabcbbe4498488e614
https://pubmed.ncbi.nlm.nih.gov/28426267
https://pubmed.ncbi.nlm.nih.gov/28426267
Autor:
J. H. Barton, Patrick Murphy, Johanna C. Bendell, Gregg C. Shepard, Noel A. Maun, Laura Blakely, Mark Mainwaring, Edward Arrowsmith, James D. Peyton
Publikováno v:
The Oncologist
Lessons Learned Neoadjuvant 5-fluorouracil, oxaliplatin, and lapatinib in combination with radiation therapy is safe for neoadjuvant treatment for patients with localized human epidermal growth receptor 2-positive esophagogastric adenocarcinoma. Eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d885cf492e4bb9bd3d2b4ce792fcda38
https://pubmed.ncbi.nlm.nih.gov/28765502
https://pubmed.ncbi.nlm.nih.gov/28765502